Lv5
890 积分 2021-09-24 加入
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
1个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
PD-1hiCXCR5– T peripheral helper cells promote B cell responses in lupus via MAF and IL-21
3个月前
已完结
Rheumatoid arthritis
3个月前
已完结
[Chinese expert consensus on off-label use of Tocilizumab in rheumatic diseases]
3个月前
已完结
Identification and management of interstitial lung disease associated with systemic sclerosis (SSc-ILD), rheumatoid arthritis (RA-ILD), and polymyositis/dermatomyositis (PM/DM-ILD): development of expert consensus-based clinical algorithms
3个月前
已完结
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
3个月前
已完结
Colchicine in Patients with Chronic Coronary Disease
4个月前
已完结
Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
4个月前
已完结
Low-dose colchicine: a new tool in the treatment of chronic coronary disease? Comment on the low-dose colchicine (LoDoCo)2 trial
4个月前
已完结
皖公网安备34019202002308
